UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16
OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2019

Commission file number: **001-38775**

ITAMAR MEDICAL LTD.

(Name of registrant)

9 Halamish Street, Caesarea 3088900, Israel
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

EXPLANATORY NOTE

Itamar Medical Ltd. hereby provides its investors presentation, which is attached to this Form 6-K as Exhibit 99.1.

Exhibits

Exhibit Number	Description
99.1	Itamar Medical Ltd., investors presentation, August 2019.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ITAMAR MEDICAL LTD.

By: /s/ Shy Basson
Shy Basson
Chief Financial Officer

Date: August 22, 2019

Exhibit 99.1

Itamar Medical

Investor Presentation

August 2019

itamar medical | Health Being Made Simple

Disclaimer

Itamar Medical Ltd. (the "**Company**") is furnishing this presentation and any information given during this presentation, solely for the consideration of eligible investors who have the knowledge and experience in financial and business matters and the capability to conduct their own due diligence investigation in connection with the investment outlined herein. Prospective investors are urged to conduct an independent evaluation of the Company.

This presentation does not constitute an offer or a solicitation to participate in any investment in the Company. This presentation does not constitute an offer to sell, or the solicitation of an offer to buy, any of the securities of the Company in the United States or Israel. The offering of the Company's securities (including all underlying securities thereof) has not been, nor will it be, registered under the United States Securities Act of 1933, as amended (the "1933 Act"), any state securities laws, or Israeli securities laws and such securities may not be offered or sold within the United States, or to, or for the account or benefit of, U.S. persons, except pursuant to an effective registration statement under the 1933 Act or an applicable exemption from the U.S. registration requirements.

The statements in this presentation should not be regarded as a basis for an investment decision of any kind, or as recommendation or opinion, or a substitute for investor discretion.

Forward Looking Statements

This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of applicable securities laws. Statements preceded by, followed by, or that otherwise include the words "believes", "expects", "anticipates", "intends", "estimates", "plans", and similar expressions or future or conditional verbs such as "will", "should", "would", "may" and "could" are generally forward-looking in nature and not historical facts. For example, when we discuss growing appreciation within the cardiology community of the role of WatchPAT, we are using forward-looking statements. Because such statements deal with future events, they are subject to various risks, uncertainties and assumptions, including events and circumstances out of the Company's control and actual results, expressed or implied by such forward-looking statements, could differ materially from the Company's current expectations. Factors that could cause or contribute to such differences include, but are not limited to, risks, uncertainties and assumptions discussed from time to time by the Company in reports filed with, or furnished to, the Israel Securities Authority and the U.S. Securities and Exchange Commission. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

The United States and Israeli securities laws prohibit any person who has material non-public information about a company ("**Inside Information**"), from purchasing or selling securities of such company, or from communicating such information to any other person under circumstances in which it is reasonably foreseeable that such person is likely to purchase or sell such securities. Statements in this presentation and in any information given during this presentation might be considered as Inside Information, in accordance with the Securities Law. Therefore, any person aware of this presentation or of any information given during this presentation, may neither use, nor cause any third party to use, any Inside Information or any other information provided in connection with the presentation, in contravention of the Securities Law or any such rules and regulations thereunder. The Company, and its respective affiliates, employees and representatives expressly disclaim any and all liability relating to or resulting from the use of this presentation or any information given during this presentation or such other information by a prospective investor or any of its affiliates or representatives.

** The contents of any website or hyperlinks mentioned in this presentation are for informational purposes and the contents thereof are not part of this presentation.*

itamar medical

Itamar Medical Mission

World Leader in Sleep Apnea Management Solutions for the Cardiology Market

www.itamar-medical.com
www.cardiosleepsolutions.com

Leader in Diagnostics of Sleep Apnea to the Cardio Space

- Flagship product: WatchPAT® is a fast growing home sleep apnea test ("HSAT")
- Sleep Apnea market growing at record rates propelled by cardiology, obesity and stress
- Increasing traction among cardiologists supported by new guidelines and direct US sales force
- Quarter-over-quarter revenue growth
- Multiple regulatory approvals (FDA, CE, MHLW), broad insurance coverage
- Experienced management team and board members with proven success

itamar medical

The Market

The Sleep Market

- ✓ 25% of adults worldwide suffer from sleep apnea[1]
- ✓ 170 million people in North and South America suffer from sleep apnea[2]
- ✓ About 80% in the US alone are undiagnosed[3]
- ✓ The diagnostic and treatment market is valued at $3.5 billion[4]

The Cardiology Market

92 million cardiovascular patients in the United States[5]

- ✓ ~50% of patients suffer from sleep apnea
- ✓ ~80% or more remain undiagnosed[6]

itamar medical

Sources:

1) American Academy of Sleep Medicine, Peppard, et al., American Journal of Epidemiology (2013)
2) "ResMed: New Analysis Shows Sleep Apnea More Common in Americas than Previously Thought." Contify Life Science News 10 June 2019.
3) Obstructive Sleep Apnea: Preoperative Assessment, Seet & Chung, Anesthesiology Clin 28 (2010) 199–215
4) Fisher & Paykel, FY2016 Half Year results Presentation (Dx & Tx)
5) Heart Disease and Stroke Statistics 2017 At-a-Glance
6) Sleep Apnea and Cardiovascular Disease, JACC Vol. 52, No. 8, 2008, August 19, 2008:686–717

Sleep Apnea - A Significant Comorbidity to Most Cardiac Disease



Source: Obstructive Sleep Apnea: Preoperative Assessment, Seet & Chung, Anesthesiology Clin 28 (2010) 199–215

itamar medical

Trends Propelling the Market



Source: Sleep Apnea Types, Mechanisms, and Clinical Cardiovascular Consequences, Javaheri,et al, JACC VOL. 69, NO. 7, 2017 841-58

itamar medical

Increased Risks of Leaving Sleep Apnea Untreated



2x Increased risk of stroke[1]

2x Risk of death from sudden cardiac arrest[2]

5x Risk of death from cardiovascular disease[3]

42% Increased risk of recurrence of atrial fibrillation following ablation[4]

Sources:
1) Sleep Apnea and Incident Stroke, Redline et al, The Sleep Heart Health Study. American Journal of Respiratory and Critical Care Medicine Vol 182 2010;
2) Obstructive Sleep Apnea and the Risk of Sudden Cardiac Death Gami et al, J Am Coll Cardiol 2013:
3) Young et al, J Sleep 2008;
4) Effect of Obstructive Sleep Apnea Treatment on Atrial Fibrillation Recurrence Shukla, Chinitz JACC Clinical Electrophysiology Vol 1 ,No 1-2 , 2015

itamar medical

The American Academy of Sleep Medicine Officially Adopts Itamar Medical's Technology for the Diagnosis of Sleep Apnea

The leading U.S. medical organization for the treatment of sleep disorders began officially recognizing the PAT technology in its guidelines for clinical practice in 2017

Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An Update for 2017

An American Academy of Sleep Medicine Clinical Practice Guideline

Vishesh K. Kapur, MD, MPH[1]; Dennis H. Auckley, MD[2]; Susmita Chowdhuri, MD[3]; David C. Kuhlmann, MD[4]; Reena Mehra, MD, MS[5]; Kannan Ramar, MBBS, MD[6]; Christopher G. Harrod, MS[7]

[1]University of Washington, Seattle, WA; [2]MetroHealth Medical Center and Case Western Reserve University, Cleveland, OH; [3]John D. Dingell VA Medical Center and Wayne State University, Detroit, MI; [4]Bothwell Regional Health Center, Sedalia, MO; [5]Cleveland Clinic, Cleveland, OH; [6]Mayo Clinic, Rochester, MN; [7]American Academy of Sleep Medicine, Darien, IL

A technically adequate HSAT device incorporates a minimum of the following sensors: nasal pressure, chest and abdominal respiratory inductance plethysmography (RIP) and oximetry; or peripheral arterial tonometry (PAT) with oximetry and actigraphy. For additional information regarding HSAT sensor requirements, refer to the AASM Manual for the Scoring of Sleep and Associated Events.[21]

Source: J Clin Sleep Med. 2017 Mar 15; 13(3): 479–504

itamar medical

WatchPAT - Simple, Accurate, Reliable

A comprehensive HSAT utilizing proprietary PAT and other signals to calculate True Sleep Time and Complete Sleep Architecture to accurately and reliably diagnose both obstructive and central sleep apnea

The traditional way:
Cumbersome sleep labs



WatchPAT™

itamar medical

WatchPAT 300 - The Next Generation WatchPAT



A New Design

- 25% reduced weight for patient comfort
- More comfortable wrist strap
- Detachable design for easier cleaning

One Stop Preparation

- 92% faster download time (3 min to 15 sec)
- Improved workflow with new disposable battery
- Compatible with both disposable and rechargeable standard AAA batteries

itamar medical

Strategy Implementation - A Unique Comprehensive Solution that Enables Diagnosis and Treatment

Total Sleep Solution™

Itamar provides cardiologists with a comprehensive sleep solution, combining diagnostics and therapy

itamar medical

WatchPAT: Integrated Platform To Diagnose and Treat Sleep Apnea

A One-Stop Sleep Apnea Solution for Cardiologists

Screening

Systematic Screening with Questionnaire

- Patient awareness kits
  - Waiting room video
  - Waiting room posters
  - Informative brochure

Diagnosing

Diagnosis with WatchPAT

- IDTF
- WatchPAT Direct
- Interpretation through CloudPAT collaboration with Sleep Physician

Treatment

Treatment

- Access to DMEs Networks for CPAP
- Compliance Programs
- PAMs Distribution

Reporting

Patient Compliance Reporting

- Waiting list
  - WatchPAT
  - Test result
  - CPAP
- Patient CPAP compliance rate
- Sleep Apnea prevalence rate

SleePATh™
Integrated Sleep Apnea Patient Care Pathway

itamar medical

Sleep Monitoring Platform - SleePATh

Integrated Sleep Apnea Patient Care Pathway for Cardiac Patients

- **CloudPAT** is a HIPPA-compliant cloud-based IT solution for convenient sleep diagnosis and secure patient data transfers that streamlines user workflow through online access for sleep report interpretation
- **SleePATh** is a dashboard that enables the physician to track their patient's sleep apnea management pathway



itamar medical

Multiple Business Models for Different Needs

itamar medical

WatchPAT Direct Program – Streamlining the HSAT

A Customizable Workflow to Enlarge the HSAT Coverage



itamar medical

Maximizing Value at a Fast Growing Market

- Making "Total Sleep Solution" available to cardiologists
- Adding additional business model of Test as a Service ("TaaS")
- Cardiology centered marketing and sales
- Adoption of PAT based technology by the Organization of Sleep Specialists

itamar medical

Revenue Growth
Non IFRS Operating Loss

itamar medical | Health Being Made Simple

Total and US Revenue



	December 31st, 2017A	December 31st, 2018A	December 31st , 2019E***
# of US Territories	16**	19**	27***

* Q over PY Q

** Including three verticals – Kaiser, VA and Dental

*** This represents forward looking statements as set forth in Slide 2 above

itamar medical

Operating Loss – Non IFRS*

* For IFRS operating loss and reconciliation between IFRS and Non-IFRS operating loss, see Slides 24 & 25, respectively

itamar medical

Thank You!

itamar medical | Health Being Made Simple

Simplicity of Pulse Oximetry the Accuracy of PSG

PARAMETERS

8+ parameters **+ sleep stages, + true sleep time**	Lab PSG 	Home PSG	**WatchPAT** Completion rate 99% vs 82%* Misdiagnosis 3% vs 19%** Central Apnea DX
4-5 parameters AHI, RDI, snoring, position		Cardio Pulmonary Systems	
1-2 parameters saturation motion			Pulse Oximetry

SIMPLICITY / COMFORT

* "US and European Sleep Disorder Diagnostic Devices Market", Frost & Sullivan ; M9AC-54 February 2014
** "Comparison of Apnea Hypopnea Index (AHI) Using Recording Time vs. Sleep Time"; Schutte-Rodin; SLEEP Volume 37, 2014

itamar medical

CMS 2019 Fee Schedule - Fact Sheet

- On Nov 1st 2018, CMS (Centers for Medicare & Medicaid Services) announced "2019 Fee Schedule for Home Sleep Apnea Testing Devices"
- **PAT-based** HSAT devices with sleep time (WatchPAT is the only HSAT using PAT technology and true sleep time) has Global reimbursement rate **23% higher** than devices with no sleep time

CPT® / HCPCS CODE[1]	MODIFIER	DESCRIPTION	2019 RVUs	2019 NATIONAL AVERAGE PAYMENT [2]
95800	Global	Sleep study, unattended, simultaneous recording; heart rate, oxygen saturation, respiratory analysis (e.g., by airflow or peripheral arterial tone), and sleep time	4.79	$173
95800	TC	Sleep study, unattended, simultaneous recording; heart rate, oxygen saturation, respiratory analysis (e.g., by airflow or peripheral arterial tone), and sleep time	3.59	$129
95800	26	Sleep study, unattended, simultaneous recording; heart rate, oxygen saturation, respiratory analysis (e.g., by airflow or peripheral arterial tone), and sleep time	1.20	$43
G0400		Home sleep test (HST) with type iv portable monitor, unattended; minimum of 3 channels	N/A	Carrier Determined

- CME fee schedule proposal for Jan 2020 was published 30 Jul 2019:
  Code 95800 - $172.63 (2019) $168.18 (2020) - (-2.5%).
  Code 97806 - $ 140.55 (2019) $119.46 (2020) - (-15%).
  The code used for WP with sleep time , if CMS adopt its recommendation , will be **41% Higher.**

itamar medical

Revenues by Geographic Area



Quarterly Operating Loss - IFRS

itamar medical

Use of Non-IFRS Measures & Reconciliation of IFRS to Non-IFRS Operating Loss

In addition to disclosing financial results prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB), this presentation contains Non-IFRS financial measures for operating loss, which are adjusted from results based on IFRS to exclude: (i) share-based payments; (ii) depreciation and amortization; (iii) change in provision for doubtful and bad debt; (iv) expenses relating to reduction in manpower.

Management believes that the Non-IFRS financial measures provided in this presentation are useful to investors' understanding and assessment of the Company's performance. Management uses both IFRS and Non-IFRS measures when operating and evaluating the Company's business internally and therefore decided to make these Non-IFRS adjustments available to investors. The presentation of this Non-IFRS financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with IFRS. For further details, see a reconciliation of operating loss and net loss on an IFRS basis to a Non-IFRS basis that is provided in the table below:

	Q1 2016	Q2 2016	Q3 2016	Q4 2016	Q1 2017	Q2 2017	Q3 2017	Q4 2017	Q1 2018	Q2 2018	Q3 2018	Q4 2018	Q1 2019	Q2 2019
IFRS operating loss	$3.5M	$2.1M	$2.0M	$2.4M	$2.2M	$1.5M	$1.3M	$0.9M	$0.9M	$0.9M	$0.8M	$0.5M	$1.3M	$1.7M
Share-based payment	$0.8M	$0.3M	$0.4M	$0.3M	$0.5M	$0.3M	$0.4M	$0.2M	$0.3M	$0.3M	$0.3M	$0.2M	$0.2M	$0.3M
Depreciation and amortization	$0.1M	$0.1M	$0.1M	$0.2M	$0.1M	$0.1M	$0.1M	$0.2M	$0.1M	$0.1M	$0.1M	$0.1M	$0.1M	$0.2M
Change in provision for doubtful and bad debt	$0.4M	-	-	$0.4M	-	-	$0.1M	-	-	$0.1M	$0.1M	-	-	$0.2M
Expenses relating to change in manpower	-	-	-	-	$0.2M	$0.1M	-	-	-	-	-	-	-	$0.1M
Non - IFRS operating loss	$2.2M	$1.7M	$1.5M	$1.5M	$1.4M	$1.0M	$0.7M	$0.5M	$0.5M	$0.4M	$0.3M	$0.2M	$1.0M	$0.9M

itamar medical